A lipid hypothesis: prediction, observation and the triglyceride/HDL gap.
Lowering serum lipid levels prevents myocardial infarctions. But are we targeting the right lipoproteins in our preventive therapy? Are we getting the maximum benefit? Triglycerides certainly deserve more attention than they have yet received. Most of the trials of lipid-lowering therapy have ignored them and this omission may explain the divergence between the fall in morbidity predicted from the epidemiological evidence and the reductions observed in the clinical trials. The evidence that the statins reduce coronary morbidity and mortality, and that this reduction is associated with a fall in LDL cholesterol, is overwhelming. But the potential value of the statins may be limited by their relative inability to increase the concentration of cardioprotective HDL. The fibrates, either alone, or in combination with a statin, retain a central role in the management of patients with mixed hyperlipidaemia who are undoubtedly at high risk of premature coronary artery disease.
BARC Asia Pacific Pte Ltd, Jakarta.
J P
JP
Deslypere
G
G
Jackson
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood* / Q000502:physiology; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood* / Q000502:physiology
D000924:Anticholesteremic Agents; D008055:Lipids; D008075:Lipoproteins, HDL; D014280:Triglycerides; D002784:Cholesterol